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Introduction
IgE has traditionally been linked to allergic Type 1 hyper-
sensitivity reactions. However, just over four decades ago, 
antinuclear autoantibodies of IgE class were detected in RA 
and SLE patients and it was hypothesized that IgE may have 
a pathophysiological role in autoimmunity [45]. This asso-
ciation between IgE and autoimmunity was a revolutionary 
concept in the field of hypersensitivity.
A pathophysiological role of IgE is observed in several 
autoimmune diseases ranging from systemic ones, like SLE 
[16], to tissue-specific ones, like Graves’ disease [50]. Fur-
thermore, IgE autoantibodies also seem to be pathogenic in 
certain allergic conditions, like atopic dermatitis (AD). It is 
believed that IgE autoantibodies may attack keratinocytes in 
AD [1], an observation which raises questions as to whether 
AD is primarily atopic or autoimmune in nature, or a com-
bination of both.
Pemphigoid is a group of autoimmune disorders in which 
autoantibodies attack the structural proteins comprising the 
junction of the epidermal and dermal layers of the skin [52]. 
Pemphigoid disorders manifest themselves clinically through 
severe blistering of the skin and superficial layers of the 
mucosa [52]. BP is the most common pemphigoid disor-
der, accounting for ~ 80% of all cases [49], and is the most 
common skin autoimmune disease of blistering character. 
It affects males and females equally, and it is considered 
mainly a disorder of old age, with the mean age of disease 
onset being 80. In the UK, it is estimated that there are 43 
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cases of BP per 1 million of the population [58], with a 
doubling of reported cases across Europe in the past decade 
[52]. BP causes relapses of inflammation in the sub-epider-
mal skin layers, resulting in local or widespread blisters, 
rash and pruritus. The underlying pathophysiological mecha-
nisms involve an immune attack on the autoantigen BP 180/
BPAg2, which is a type XVII collagen (COL17) protein act-
ing as the adhesion molecule between the epidermis and the 
basement membrane of the dermis. What distinguishes BP 
from other autoimmune blistering skin diseases is the pres-
ence of accumulated IgG on the superficial surface (rather 
than the dermal surface) of the epidermis in the blistered 
areas of the skin. Treatment is heavily dependent on the use 
of topical and systemic corticosteroids.
Studies on BP patients show elevated IgE class autoanti-
bodies with a pathophysiological role. Evidence lies within 
the detection of IgE autoantibodies targeting the BP180 
adhesion molecule and leading to the manifested symptoms 
[18]. In addition, omalizumab, a humanized monoclonal 
anti-IgE antibody that was originally designed to control the 
symptoms of persisting severe asthma following corticoster-
oid and β2 agonist treatment [9], has proven to be effective 
in treating the symptoms of BP in human subjects [20, 21].
With this information in hand, we decided to carry out a 
systematic literature review to determine, through analysis 
of the studies available, whether there is validity in the find-
ings of IgE autoantibodies in BP, and if so, whether the pres-
ence of elevated IgE autoantibody levels affects the severity 
of the phenotype and/or the course of the disease.
Methods
MEDLINE was accessed through PubMed, EMBASE 
through OVID and WEB OF SCIENCE through the Wiley 
Online Library. Each database was searched with the term 
‘(ige or immunoglobulin e) and (bullous pemphigoid or bp)’ 
on 15 October 2016. This yielded a total of 1084 records 
as follows: MEDLINE, 496; EMBASE, 31; WEB OF SCI-
ENCE, 557. At this initial stage, for comparison between 
disease, searches were also performed for IgE in chronic 
idiopathic urticaria (656 records) and IgE autoantibodies 
in atopic dermatitis (281 records), giving a total of 2021 
records. Figure 1 shows the PRISMA 2009 flow diagram 
used to illustrate the study selection process for the system-
atic review. This shows the process of searching for records, 
removing duplicates, screening titles and abstracts, assessing 
full texts for eligibility and selecting which studies would 
be used in the analysis. This yielded 33 studies of which 19 
were used to document the chronological development of 
the occurrence of IgE autoantibodies in BP, and 16 provided 
information to assess the contribution of IgE autoantibodies 
to the severity and/or clinical phenotype of BP (2 studies 
provided information relevant to both parts of the review). 
As illustrated in Fig. 2, of all papers published on the topic 
in the past 42 years, 50% were published in the last 6 years 
(2010–2016). This indicates a rapid expansion of interest 
and investigation in the topic in recent years.
Results and discussion
Chronological development in the field 
of the relationship of IgE and BP
IgE and the pathophysiology of BP
The first findings that led to the concept that IgE may be 
linked to BP were published in 1974. Following this, in the 
1970s and 1980s, a variety of studies were conducted to 
address this hypothesis. During these two decades, blood 
sampling and testing, immunofluorescence on lesioned skin 
biopsies and chromatography using dermal infiltrate were 
the main laboratory techniques employed in this research. 
As is clearly illustrated below, the role of IgE in BP dur-
ing this time was only demonstrated in a non-specific fash-
ion: for example, through findings of IgE deposition in skin 
basement membrane (BM), elevated serum IgE levels and 
peripheral blood eosinophilia. Inevitably, it was unclear 
whether the apparent involvement of IgE in BP was of a 
pathogenic nature, or whether it was simply an epiphenom-
enon of the disease itself.
In 1974, elevated IgE levels were reported in 70% of 
patients with bullous pemphigoid [3]. In the same year, a 
study using direct and indirect immunofluorescence detected 
moderate staining of IgE on the skin BM of four (out of 16) 
BP patients, one of whom also had greatly elevated serum 
IgE [47]. Two years later, a study of tissue eosinophilia in 
BP lesions of four patients showed eosinophil chemotac-
tic activity in the infiltrate [5]; furthermore, the serum of 
half of the subjects tested positive for IgE autoantibodies 
to skin BM. In 1980, a similar study reported that 11 of 
25 BP patients had elevated serum IgE levels, and 15 of 
them tested positive for serum IgE anti-BM autoantibodies 
by indirect immunofluorescence [44]. A study in 1983 on 
28 BP patients found 50% to have peripheral blood eosino-
philia; the authors proposed that BP should be considered 
in the differential diagnosis of skin bullous conditions with 
peripheral blood eosinophilia [8].
In the early 1990s, the application of newer tech-
niques, such as ELISA, enabled better definition of the 
relationship between IgE and BP, as it was then possible 
to identify specific receptors for IgE that were possibly 
involved in the pathophysiology. By the mid-1990s, it was 
established that BP involved impaired B cell function, 
and the soluble form of CD23 (sCD23), a low affinity IgE 
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receptor (FcεRII) on haematopoietic cells, was known to 
be involved in B lymphocyte growth and differentiation. 
As a result, the role of CD23 in the pathophysiology of 
BP was investigated and elevated levels of sCD23 were 
detected in the sera of BP patients [24]. Furthermore, there 
was significant correlation between sCD23 and serum IgE 
levels in the BP patients; this correlation was not appar-
ent in the sera of non-BP control subjects. The authors 
concluded that sCD23 was an important index for moni-
toring the disease in relation to IgE abnormalities and 
impaired B lymphocyte function. A year later, the under-
standing of the involvement of sCD23 in BP was further 
advanced when it was reported that levels of sCD23 in 
the dermal bullae infiltrates of ten BP patients were sig-
nificantly higher than in the infiltrates of suction bullae 
formed in ten non-BP control subjects [51]. Again, there 
Fig. 1  PRISMA 2009 flow diagram used to illustrate the study 
selection process for the systematic review. This shows the process 
of searching for records, removing duplicates, screening titles and 
abstracts, assessing full texts for eligibility and selecting which stud-
ies would be used in the analysis
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was correlation between the serum levels of sCD23 and 
IgE levels in all ten BP patients.
Some pivotal studies in the development of the field 
showed specific autoantigens in the hemidesmosomal pro-
teins of the skin to be the targets of autoreactive IgE anti-
bodies. As discussed below, BP180 and BP230 are major 
autoantigens targeted by IgE autoantibodies in BP. BP180 
(BPAg2), a transmembrane protein, was the first autoanti-
gen characterized in BP and was found to have collagenous 
repeats in its ectodomain capable of forming collagen-like 
helices [27]; indeed, BP180 was later renamed Collagen 
XVII. BP230 (BPAg1) was first identified using sera from 
BP patients and was found to be located on the intracel-
lular domain of the hemidesmosome where it functions as 
a plakin family protein, associating keratin filaments to the 
hemidesmosome [53]. As a consequence of identifying these 
two proteins as targets of IgE autoantibodies, by the mid-
1990s, the role of IgE in BP was more widely accepted as 
being pathogenic rather than being an epiphenomenon.
A study in 1996 using a radioimmunoassay reported 12 
out of 19 BP patients to have IgE autoantibodies against the 
BP55 antigen [15]. Two years later, a study examined the 
antigenic specificity of IgE autoantibodies in 39 BP serum 
samples using ELISA, immunoblotting and immunofluores-
cence microscopy: 18 of the samples contained IgE autoanti-
bodies against either the BM or a 230 kDa epidermal antigen 
(BP230) [25]. The epitopes recognized by the autoantibod-
ies mapped primarily to the C-terminal end of the protein 
and there was strong correlation between circulating IgE 
autoantibodies and serum IgE levels. However, this study 
found no sera containing anti-BP180 IgE autoantibodies. In 
2000, immunoblotting and ELISA were used to show that 
IgE and IgG4 isotypes preferentially react with two epitopes 
within the ectodomain (NC16A) of BP180 [18]. Another 
study used double-labelling immunofluorescence to identify 
a potential effector function of IgE autoantibodies associ-
ated with their reactivity to BP180 auto-antigen: of the 30 
BP patients studied, 70% of untreated patients had elevated 
total IgE levels and 86% had detectable anti-BP180 IgE in 
their serum [17]. IgE-coated mast cells were detected in per-
ilesional skin, which were also coated with BP180 peptides. 
BP180-stimulated histamine release was notably higher in 
basophils obtained from BP patients who received no treat-
ment in contrast to patients who either received treatment 
for BP or the healthy control subjects. The attack on BP180 
by autoreactive IgE continued to be the main focus of the 
investigations for the rest of the decade. Fine mapping of 
the antigenic sites of NC16A ectodomain of BP180 showed 
similar reactivity patterns for IgE and IgG, with subregion-2 
being the major site recognized by both [23]. However, anti-
gen-specific histamine release by basophils occurred only 
in the presence of IgE autoantibodies specific for NC16A. 
In 2009, a study using immunoblotting found that 16 of 18 
serum samples contained autoreactive IgE specific for an 
epitope of the intracellular domain (ICD) of BP180, sug-
gesting that the ectodomain NC16A is not the only target 
region of IgE on BP180 [19]. The target sites on the ICD 
of BP180 play an important role in the incorporation of 
proteins into hemidesmosomal structures. The authors sug-
gested that this could be a possible pathogenic mechanism 
of IgE in BP, since tampering with the interaction of BP180 
with other hemidesmosomal constituents could lead to the 
dermal–epidermal separation observed in the affected skin 
of BP patients.
An interesting recent observation concerning the patho-
physiology of IgE in BP indicates that IgE may have FcR-
independent effects: IgE was found to stimulate FcR-inde-
pendent release of IL-6 and IL-8 by keratinocytes in vitro 
[41]. When the experiment was repeated using an organ 
(skin) culture, IL-6 and IL-8 were similarly released. 
Cytokine release was also accompanied by a decrease in 
the number of hemidesmosomal proteins located in the BM 
zone.
IgE and the diagnosis of BP
A highly sensitive method for detecting anti-BP180 NC16A 
IgE autoantibodies in sera of BP patients was reported in 
2009 [39]. The assay detected IgE autoantibodies in 77% of 
sera tested, a frequency significantly higher than previously 
reported and equivalent to that of anti-BP180 NC16A IgG 
autoantibodies. The results of the study ranked the ELISA 
method as the most sensitive, when compared with other 
techniques such as immunoblotting and IIF, and that testing 
for both IgG and IgE anti-BP180 NC16A may be a more 
efficient indicator of disease severity and predictor of treat-
ment effectiveness. Nevertheless, the authors stressed that 
Fig. 2  The number of studies published each year between 1974 and 
2016 relevant to the relationship between IgE autoantibodies and BP
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NC16A is not the only target of anti-BP180 autoantibodies, 
and that BP180 is not the only autoantigenic target in BP. 
Thus, an NC16A-specific ELISA alone may underestimate 
the actual reactivity of autoantibodies with BP180 and other 
autoantigens in BP.
More recently, Pomponi et al. evaluated the efficiency 
of the ISAC® microarray system in detecting IgE and IgG 
antibodies in BP patients [46]. The experimental version of 
ISAC® that was used included BP180 NC16A and was able 
to replicate the results of ELISA. These improvements in 
the diagnostic techniques for the detection of autoantibodies 
involved in BP are of great importance in reducing discrep-
ancies that arise in the literature due to the heterogeneity in 
the sensitivity of various laboratory assays.
IgE and the treatment of BP
The hypothesis of IgE having a pathogenic role in BP has 
been further established through the successful treatment 
of BP patients with omalizumab, a humanized monoclonal 
anti-IgE antibody which binds to IgE [60]. In 2009, Fairley 
et al. reported the use of omalizumab to treat a BP patient 
who was unresponsive to steroid treatment [21]. The team 
justified the decision based on the study of Dimson et al. [17] 
which reported that 70% of untreated BP patients presented 
with elevated total serum IgE levels and 86% presented with 
anti-BP180 NC16A IgE autoantibodies. Clinical improve-
ment was observed within 16 weeks of commencing omali-
zumab treatment. By week 1 of treatment, clinical improve-
ments included a decrease in pruritus and in bullous count 
by 44%. By week 16, there was a 45% decline in the skin 
involved in urticarial lesions and a drop in peripheral blood 
eosinophil count from 3427 to 887/mm3 (normal ≤ 475/
mm3). Four months after discontinuation of treatment, the 
patient reported pruritus and new bullae formation, but re-
initiation of omalizumb resulted in resolution of bullae and 
subsidence of pruritus. This was the first treatment targeting 
IgE in a BP patient and it was also the first in vivo dem-
onstration of the pathogenicity of IgE class autoantibodies 
in BP. Similarly, in 2012, Dufour et al. [20] reported the 
treatment with omalizumab of a 5-month-old boy suffering 
from infant BP (IBP), who was unresponsive to steroids. 
Omalizumab treatment resulted in a decline in the number 
of bullae and urticarial lesions and overall disease control 
was achieved by day 25 of treatment. Omalizumab was con-
tinued for the next 7 months and no clinical relapse occurred 
during this period. This observation supported the efficacy 
of omalizumab in treating IBP. Following these reports of 
single patient cases, a study was undertaken in which six 
patients were treated with omalizumab and monitored for up 
to 42 months [60]. Five of them benefited therapeutically: 
there was inhibition of new bullae formation, subsidence of 
pruritus, a decline in eosinophil count and a decreased need 
for immunosuppressant medication. Despite this being an 
uncontrolled study, the authors felt that the results were suf-
ficiently clear-cut to conclude that omalizumab can neutral-
ize IgE reactivity in patients with BP and control the disease.
IgE in relation to disease activity and clinical phenotype 
of BP
As the role of IgE in the pathophysiology of BP became bet-
ter understood as a pathogenic one, hypotheses about how its 
presence in BP may affect the disease severity/activity and/or 
clinical manifestations (i.e. phenotype) were put forward. Of 
the earliest papers to explore a possible correlation between 
IgE and BP activity was that of Asbrink and Hovmark [4], 
which suggested that total serum IgE was a better measure 
of disease activity in contrast to IIF. Since then, several stud-
ies conducted in the field have addressed how total serum 
IgE or, more commonly, the levels of IgE autoantibodies in 
the serum, can potentially affect the disease severity/activ-
ity and/or the phenotype of BP. This review has assessed 
the outcomes of 16 primary studies (details summarized in 
Table 1a, b) conducted between 2000 and 2016, and one 
Letter to the Editor, which address this issue.
IgE and the disease severity/activity of BP
Disease severity of BP has been defined in a variety of ways 
over the years. The severity of BP used to be assessed by 
counting the number of bullae on the skin of the patient. 
Joly et al. and Bernard et al. [6, 33] reported the use of this 
method: the larger the number of bullae, the more points 
were allocated for disease severity. Tsuji-Abe et al. and Rou-
jeau et al. [48, 55] reported the use of a similar method, but 
instead of counting individual bullae, it was the percentage 
of skin affected by lesions that was taken into consideration. 
Ishiura et al. [31], Iwata et al. [32] and Messingham et al. 
[39] also reported the use of this method and the develop-
ment of scales (unofficial, self-defined scoring scales) for 
quantifying disease severity. In 2012, the bullous pemphig-
oid disease area index (BPDAI) was introduced. This is an 
objective scale which continues to be used for assessing the 
% of skin affected by BP-related lesions (both bullous and 
erythematous) and degree of pruritus [34]. The scale ranges 
from 0 to 120 and the total BPDAI score can be calculated 
by adding together the scores for bullae, erythematous 
lesions and pruritus [57].
As shown in Table 2, nine studies [7, 11, 18, 26, 32, 34, 
39, 40, 57] found that anti-BP180 autoantibodies of IgE class 
are associated with increased severity of BP, in contrast to 
two studies [38, 42] which did not find such an association. 
The two studies which reported no association did not seem 
to have any major differences in conduct from the rest of the 
studies which did report an association. No studies reported 
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an association between anti-BP230 IgE autoantibodies and 
disease severity, while four studies [26, 31, 32, 42] stated 
that anti-BP230 IgE autoantibody serum levels or deposition 
in the skin BM showed no correlation with disease severity.
Since it has been demonstrated that total serum IgE levels 
correlate directly with the levels of IgE specific for BP180 
and BP230 antigens [35] and that there is a good positive 
correlation between circulating IgE autoantibodies and total 
serum IgE [25], some studies have sought to determine 
whether disease severity correlates with total serum IgE 
levels: three studies reported a positive correlation between 
total serum IgE levels [11, 34, 35] and disease severity and 
one study [14] reported no correlation.
Overall, the high proportion of studies reporting an asso-
ciation between anti-BP180 IgE autoantibodies and severity 
of BP compared to the studies reporting no such associa-
tion (9:2) favours a correlation between the presence of IgE 
autoantibodies and increased disease severity.
IgE and the clinical presentation of BP
Bullous pemphigoid does not manifest as a single phenotype. 
The typical bullous phenotype involves local or widespread 
blisters and eruptions; however, these can be preceded by 
lesions of an urticarial nature on erythematous skin. One 
of the less common forms of BP is pemphigoid nodularis 
(nodular phenotype) which is characterized by highly pru-
ritic lesions, often formed on nodular skin [12].
Table 3 shows the numbers of studies that have reported 
correlation (or lack of correlation) of various IgE parameters 
to the different phenotypes of BP [11, 14, 26, 42, 57, 59]. 
Overall, these studies indicate that IgE autoantibodies are 
not specifically associated with the blisters and eruptions 
seen in the typical presentation of BP. The urticarial presen-
tation of the condition has been the most investigated phe-
notype of BP with respect to parameters of IgE expression. 
However, the number of reports that IgE (total or autoanti-
body) levels are associated with urticarial lesions is equal 
to the number that found no such associations. There is thus 
insufficient evidence at present to conclude from studies in 
patients that IgE autoantibodies are associated with specific 
clinical phenotypes of BP.
Amber [2] suggested that two possible problems in 
establishing an association between IgE autoantibodies and 
the urticarial stage of BP could be variable sensitivity in 
detecting IgE autoantibodies in BP patients and insufficient 
discrimination of distinct clinical phenotypes within the 
spectrum of the disease (see also reply by Zuo [63]). Two 
other lines of investigation that indirectly provide evidence 
relevant to this issue are studies of BP in murine models, and 
studies of IgE autoantibodies in other skin diseases:
Firstly, whereas IgG-mediated murine models lack urti-
carial erythema and eosinophil infiltration, these features Ta
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occur in human skin engrafted on to SCID mice inoculated 
with monoclonal IgE specific to the BP180 ectodomain [62]. 
A similar model has been developed using human skin-
engrafted nude mice inoculated with IgE from BP patients 
[22]. Direct immunization of mice with fragments of BP180 
also induces skin lesions associated with raised IgE and 
infiltration of eosinophils [28].
Secondly, autoantibodies of IgE class have been reported 
in patients with other inflammatory skin diseases. IgE 
autoantibodies specific for double-stranded DNA [10] 
and for thyroid autoantigens [10, 13] have been described 
in some patients with chronic idiopathic urticaria; these 
autoantibodies may contribute to disease symptoms by acti-
vating mast cells and basophils [37]. IgE autoantibodies spe-
cific for a variety of autoantigens have been reported in some 
atopic dermatitis patients [29, 30, 43, 54, 56, 61] and appear 
to correlate with disease severity and chronicity [36, 54].
Limitations of this systematic review
As shown in Table 1, the studies used in this review were 
subject to several limitations. Most were conducted in a 
single-centre fashion, and only a few countries (notably, the 
USA, Japan, China and Germany) have been conducting the 
majority of research in this area. As a result, it is not known 
whether the conclusions of these studies are generalizable to 
all ethnicities. In addition, most of the studies used sample 
sizes that are small—this problem may arise because of the 
relative rarity of BP. In general, little information has been 
given about the subjects involved, other than sex and age; 
for example, about their overall health and any comorbidi-
ties they have that could constitute confounding factors, or 
about the methods whereby they were recruited. Lack of 
such information could be a warning for selection, exclusion 
and sampling bias. Another potential problem is the ambigu-
ity in the full spectrum of signs, symptoms and phenotypes 
of BP, leading to a vague consensus on the manifestations 
of the disease. This poses a risk of classification bias when 
selecting patients for a study. Moreover, procedural errors 
could lead to bias as well. For instance, several studies have 
reported an uncertain degree of sensitivity of the methods 
used in determining IgE autoantibody concentrations, and 
blinding of the scientists conducting the experiments is not 
often mentioned, raising possible detection bias. The diver-
sity in the scales used to assess the disease severity of BP 
contributes further to procedural inaccuracies. The lack of 
healthy controls and disease comparisons in numerous stud-
ies poses a risk of yielding results of questionable reliabil-
ity. Furthermore, most studies included in this review are 
retrospective studies, which pose an increased risk of recall 
bias and the influence of confounding factors compared to 
prospective studies. As with all systematic reviews, there is 
inevitably a risk of publication bias as the conclusions of the 
review are based on published data, which can be a problem 
since positive outcomes are three times more likely to be 
published than are negative outcomes. No grey literature was 
used in this review and some data were unavailable for us to 
use. Furthermore, there is a high degree of heterogeneity in 
the studies used, particularly with respect to the sample sizes 
and characteristics, the criteria for diagnosing BP, the type 
of variables investigated and the methods used for measuring 
the variables, the use of control/comparison groups and the 
actual outcomes.
Conclusion
This review’s results support the conclusion that the higher 
the serum IgE autoantibody levels are, the more severe the 
manifestation of BP will be; however, they do not support 
the possibility that higher IgE autoantibody levels promote a 
more urticarial presentation of BP. It is fair to say that there 
is ambiguity as to whether IgE can be held accountable for 
the full spectrum of BP manifestations, or whether its effects 
are more relevant to the initial stages of the disease. Fur-
ther research is needed in the future to establish more solid 
Table 3  The number of studies reporting that a specific parameter of IgE can or cannot affect the clinical manifestation (phenotype) of BP 
[Refs]
Correlation with 
anti-BP180 IgE 
aabs
No correlation 
with anti-BP180 
IgE aabs
Correlation with 
anti-BP230 IgE 
aabs
No correlation 
with anti-BP230 
IgE aabs
Correlation with 
unspecified IgE 
aabs
Correlation with 
total serum IgE
No cor-
relation
with total 
serum 
IgE
Bullous 0 2 [11, 57] 0 0 0 1 [14] 0
Urticarial Erythe-
matous
2 [11, 42] 3 [7, 26, 57] 1 [42] 1 [26] 1 [59] 0 1 [14]
Bullous/erythe-
matous
0 1 [26] 0 1 [26] 0 0 0
Nodular 2 [26, 42] 0 2 [26, 42] 0 0 0 0
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conclusions. There is a need for more multi-centre prospec-
tive cohort studies which would help to eliminate uncertain-
ties in the field, particularly with respect to a possible asso-
ciation between the occurrence of IgE class autoantibodies 
and the clinical phenotype of BP.
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